The relation of the dynamics of anthropometric data in obese women of childbearing age with treatment type

Main Article Content

S.I. Ismailov
M.B. Abduvakhabova


Background. The aim was to study efficiency of pathogenetic therapy and dynamics of anthropometric indexes in obese women of childbearing age having different endocrine patho­logy before and 6 months later after treatment. Materials and methods. Under an etiologic factor the obese patients were divided into three groups: with polycystic syndrome of ovaries (PCOS) (n = 30), hypothalamic obesity (n = 21) and with obesity and primary hypothyroidism (n = 20). All patients were examined using biochemical, hormonal methods of research, magnetic resonance tomography of pituitary. Results. The patients of the first and second groups had significant decrease of body mass index (BMI) after 6 months of treatment, while patients of the third group did not attain significant decrease of BMI over 6 months of treatment. In addition, 10 patients of the first group became pregnant (19.5 %). The patients of the first and second groups had significant improvement of indexes as compared to average data of waist circumference and waist — hip ratio against the treatment, while the patients of the third group did not find significant changes of those indexes over 6 months of treatment. Conclusions. The treatment with metformine in obese patients significantly improves clinical indices and declines BMI. Optimization of treatment of obesity in women of reproductive age is based on the individual programs, the choice of which is determined by the values of anthropometric indices, hormonal and metabolic status, features of food behavior and personality-emotional sphere, menstrual and reproductive functioning. Realization of curative measures complex considering the worked out algorithm of individual selection of obesity therapy allows reduce effectively and retain the attained body weight, improves somatic and reproductive health for the women of reproductive age.

Article Details

How to Cite
Ismailov, S., and M. Abduvakhabova. “The Relation of the Dynamics of Anthropometric Data in Obese Women of Childbearing Age With Treatment Type”. INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine), vol. 13, no. 2, May 2017, pp. 123-7, doi:10.22141/2224-0721.13.2.2017.100599.
Original Researches


Glintborg D, Andersen M. An update on the pathogenesis, inflammation, and metabolism in hirsutism and polycystic ovary syndrome. Gynecol Endocrinol. 2010;26(4):281-96. Epub 2010/02/10. doi: 10.3109/09513590903247873.

Garruti G, Depalo R, Vita MG, Lorusso F, Giampetruzzi F, Damato AB et al. Adipose tissue, metabolic syndrome and polycystic ovary syndrome: from pathophysiology to treatment. Reprod Biomed Online. 2009;19(4):552-63. Epub 2009/11/17. PMID: 19909598.

Samad F, Badeanlou L, Shah C, Yang G. Adipose tissue and ceramide biosynthesis in the pathogenesis of obesity. Adv Exp Med Biol. 2011;721:67-86. Epub 2011/09/13. doi: 10.1007/978-1-4614-0650-1_5.

Ouchi N, Parker JL, Lugus JJ, Walsh K. Adipokines in inflammation and metabolic disease. Nat Rev Immunol. 2011;11(2):85-97. doi: 10.1038/nri2921. PMCID: PMC3518031.

Mangge H, Almer G, Truschnig-Wilders M, Schmidt A, Gasser R, Fuchs D. Inflammation, adiponectin, obesity and cardiovascular risk. Curr Med Chem. 2010;17(36):4511-20. PMID: 21062254.

Toulis KA, Goulis DG, Mintziori G, Kintiraki E, Eukarpidis E, Mouratoglou SA et al. Meta-analysis of cardiovascular disease risk markers in women with polycystic ovary syndrome. Hum Reprod Update. 2011;17(6):741-60. Epub 2011/06/02. doi: 10.1093/humupd/dmr025.

Chakrabarti J. Serum leptin level in women with polycystic ovary syndrome: correlation with adiposity, insulin, and circulating testosterone. Ann Med Health Sci Res. 2013;3(2):191-6. Epub 2013/08/07. doi: 10.4103/2141-9248.113660. PMCID: PMC3728861.

Yildizhan R, Ilhan GA, Yildizhan B, Kolusari A, Adali E, Bugdayci G. Serum retinol-binding protein 4, leptin, and plasma asymmetric dimethylarginine levels in obese and nonobese young women with polycystic ovary syndrome. Fertil Steril. 2011;96(1):246-50. Epub 2011/05/24. doi: 10.1016/j.fertnstert.2011.04.073.

Costello M, Shrestha B, Eden J, Sjoblom P, Johnson N. Insulin-sensitising drugs versus the combined oral contraceptive pill for hirsutism, acne and risk of diabetes, cardiovascular disease, and endometrial cancer in polycystic ovary syndrome. Cochrane Database Syst Rev. 2007;(1):CD005552. Epub 2007/01/27. doi: 10.1002/14651858.CD005552.pub2.

Basios G, Trakakis E, Chrelias C, Panagopoulos P, Vaggopoulos V, Skarpas P et al. The impact of metformin treatment on adiponectin and resistin levels in women with polycystic ovary syndrome: a prospective clinical study. Gynecol Endocrinol. 2015;31(2):136-40. doi: 10.3109/09513590.2014.975684.

Hamed HO. Role of adiponectin and its receptor in prediction of reproductive outcome of metformin treatment in patients with polycystic ovarian syndrome. J Obstet Gynaecol Res. 2013;39(12):1596-603. Epub 2013/07/24. doi: 10.1111/jog.12101.

Most read articles by the same author(s)

1 2 3 > >>